Compare MNSB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNSB | CRBP |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 168.3M |
| IPO Year | 2017 | 2014 |
| Metric | MNSB | CRBP |
|---|---|---|
| Price | $24.39 | $9.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 29.7K | ★ 247.9K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 210.00 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $135,615,000.00 | $4,822,272.00 |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $3.77 | $116.00 |
| P/E Ratio | $23.32 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $17.86 | $7.12 |
| 52 Week High | $25.29 | $20.56 |
| Indicator | MNSB | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 55.55 |
| Support Level | $23.58 | $8.30 |
| Resistance Level | $25.16 | $9.66 |
| Average True Range (ATR) | 0.53 | 0.53 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 94.65 | 58.72 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.